%D8%AF%D9%88%D8%AA%D8%A7%D8%B3%D8%AA%D9%8A%D8%B1%D8%A7%D9%8A%D8%AFCategory:DutasterideDwtasteridDutasteridDutasterideDutasteridaDutasteridiDutasteridDutasteride%E3%83%87%E3%83%A5%E3%82%BF%E3%82%B9%E3%83%86%E3%83%AA%E3%83%89Dutasteride%E0%AC%A1%E0%AD%81%E0%AC%9F%E0%AC%BE%E0%AC%B8%E0%AD%8D%E0%AC%9F%E0%AD%87%E0%AC%B0%E0%AC%BE%E0%AC%87%E0%AC%A1DutasterydDutasteridDutasteridDutasterid%D0%94%D1%83%D1%82%D0%B0%D1%81%D1%82%D0%B5%D1%80%D0%B8%D0%B4DutasterideQ424760
about
P3781
Dutasteride to Treat Women With Menstrually Related Mood DisordersThe Role of 5-alpha Reductase in Mediating Testosterone ActionsPROS-1-Male Hormonal Contraceptive Regimens on Prostate TissueEffects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without CatheterDutasteride (GI198745) In Benign Prostatic Hyperplasia SubjectsAssessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In MenLong-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate TissueBioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for BrachytherapyPharmacogenetics of Alcohol: Treatment ImplicationsStudy to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male SubjectsStudy of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerFor Cause Prostate Biopsy in REDUCE Population TrialA Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mgCombination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate CancerAn Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mLEconomic Analyses of the REDUCE TrialDemonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic HyperplasiaDutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor UseFeasibility of Hormones and Radiation for Intermediate or High Risk Prostate CancerAVODART(Dutasteride) Post-marketing Surveillance(PMS)Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate EnlargementDutasteride Versus Placebo and Finasteride in Men With Androgenetic AlopeciaDutasteride Treatment for the Reduction of Heavy Drinking in Men
P4844
Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasiaThe efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis5-alpha-dihydrotestosterone elevations associated with phentermine use
P921
Q61865351-FBB681C3-DCB1-4A97-8E9D-20981C6A02DBQ61917748-C45FA81D-8C0F-44F2-8BAC-57505EFA11EFQ61918048-B9063634-0D3E-4DE6-8318-CF0950BDC59FQ61921873-5B4E2B37-6046-4A47-B990-D5C33D5ED8FFQ61933627-B7E75F03-B7CB-4040-AD7F-659CD14DBE12Q61934700-9477711E-C52B-4D78-910E-77193312EF22Q61955386-90EDC73C-A46F-458F-9BB2-E8AAF8777AABQ61955532-3333C4D4-816B-447D-B0EA-CA83C95728F9Q61980981-5C8E92E3-6CCE-46B6-9621-BFF18B31DCD8Q63063545-36170C74-AB4B-4D03-A907-0939D8B37AAEQ63315586-3B8E0899-6F56-4F3D-8093-A5ED6703B16CQ63316712-7D5A6F30-1C7F-4D1B-B857-4C2BF1F313ABQ63317589-BE3DBBB1-7744-4BCA-9A57-21BB7709FF26Q63319545-98CA140F-6D97-4343-8E56-65347281677BQ63320466-7470272A-F945-4971-9C53-8CF4A1CA496BQ63334343-2C61E70E-934E-4C6B-9D8C-CD1D1BF87F90Q63335662-8836BA30-66BC-4FB1-B6C4-DEEE5AC17D67Q63336389-4AB897DD-DBCC-4696-88E8-632C7F1E8FDCQ63337235-167C3CEF-705D-4635-A9D0-8344AA49F819Q63337587-0B933ED6-19D3-48E1-AB8E-83FF2620EB4EQ63338416-581D55CC-6FE1-4A21-81C1-AF4F397551ACQ63339370-90948294-1436-46EA-B489-DA29D3CD830DQ63341069-A2024C2E-B928-444C-A2F8-CB119B626C84Q63572492-F095E8A9-F52A-4560-855F-C84EB36BA4D7
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dutasterid
@de
Dutasterid
@sh
Dutasterid
@sr
Dutasterid
@tr
Dutasterida
@es
Dutasteride
@it
Dutasteride
@vi
Dutasteridi
@fi
avodart
@ru
dutasterid
@id
type
label
Dutasterid
@de
Dutasterid
@sh
Dutasterid
@sr
Dutasterid
@tr
Dutasterida
@es
Dutasteride
@it
Dutasteride
@vi
Dutasteridi
@fi
avodart
@ru
dutasterid
@id
altLabel
(5alpha,17beta)-N-(2,5-bis(tri ...... zaandrost-1-ene-17-carboxamide
@cy
(5alpha,17beta)-N-(2,5-bis(tri ...... zaandrost-1-ene-17-carboxamide
@en
Avidart
@fi
Avodart
@fi
Avodart®
@cy
Avodart®
@id
Avolve
@fi
Duagen
@fi
Duprost
@fi
Dutagen
@fi
prefLabel
Dutasterid
@de
Dutasterid
@sh
Dutasterid
@sr
Dutasterid
@tr
Dutasterida
@es
Dutasteride
@it
Dutasteride
@vi
Dutasteridi
@fi
avodart
@ru
dutasterid
@id